Table 1.
Baseline demographic and clinical Characteristics.
| Characteristic | Pre-COVID-19 2019 cohort (N = 923) | Post-COVID-19 2020 cohort (N = 796) |
|---|---|---|
| Age, year | ||
| Mean (SD) | 69 (10) | 69 (10) |
| Median (IQR) | 70 (62,76) | 70 (62,76) |
| Gender, n (%) | ||
| Male | 482 (52.2) | 426 (53.5) |
| Female | 441 (47.8) | 370 (46.5) |
| Race, n (%) | ||
| White | 532 (57.6) | 419 (52.6) |
| Other | 139 (15.1) | 156 (19.6) |
| Black | 81 (8.8) | 66 (8.3) |
| Asian | 18 (2.0) | 19 (2.4) |
| Unknown | 101 (10.9) | 95 (11.9) |
| Hispanic or Latino ethnicity, n (%) | 52 (5.6) | 41 (5.2) |
| Region, n (%) | ||
| South | 393 (42.6) | 343 (43.1) |
| Northeast | 128 (13.9) | 105 (13.2) |
| West | 125 (13.5) | 125 (15.7) |
| Midwest | 93 (10.1) | 84 (10.6) |
| Unknown (academic center-blinded) | 184 (19.9) | 139 (17.5) |
| Stage at initial diagnosis, n (%) | ||
| Stage I | 53 (5.7) | 60 (7.5) |
| Stage II | 151 (16.4) | 79 (9.9) |
| Stage III | 79 (8.6) | 63 (7.9) |
| Stage IV | 575 (62.3) | 555 (69.7) |
| Unknown | 65 (7.0) | 39 (4.9) |
| Site of primary tumor, n (%) | ||
| Head | 476 (51.6) | 397 (49.9) |
| Tail | 168 (18.2) | 177 (22.2) |
| Body | 163 (17.7) | 130 (16.3) |
| Overlapping sites | 90 (9.8) | 68 (8.5) |
| Pancreas, NOS | 26 (2.8) | 24 (3.0) |
| ECOG PS score, n (%) | ||
| 0 | 191 (20.7) | 152 (19.1) |
| 1 | 257 (27.8) | 229 (28.8) |
| 2+ | 75 (8.1) | 87 (10.9) |
| Missing | 400 (43.3) | 328 (41.2) |
| Received first-line therapy, n (%) | 700 (75.8) | 609 (76.5) |
| Received second-line therapy, n (%) | 263 (28.5) | 109 (13.7) |
| Clinic visit within 90 days of mPDAC diagnosis, n (%) | 872 (94.5) | 782 (98.2) |
| Days to first clinic visit | ||
| Mean (SD) | 10 (12) | 10 (13) |
| Median (IQR) | 7 (2-14) | 7 (2-14) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; IQR, interquartile range; mPDAC, metastatic pancreatic ductal adenocarcinoma.